Hospira Infant Dextrose Injection Recall: Hair Particulates in Syringes
Hospira recalls infant dextrose injection syringes containing human hair particles. This could cause blockages or reactions in infants. Stop using affected units immediately.
Stop using this now
Presence of Particulate Matter: human hair found within an internal sample syringe.
Contact the company
What happened, in plain English
Hospira is recalling infant dextrose injection syringes that contain human hair particles. This could cause blockages or reactions in infants, so affected units should be stopped using immediately. Read more at govinfonow.com/recall/41641-hospira-infant-dextrose-injection-recall-hair-particulates-in-syringes.
Source Summary by GovInfoNow · govinfonow.com/recall/41641-hospira-infant-dextrose-injection-recall-hair-particulates-in-syringes · Updated October 8, 2026 · FDA enforcement record: FDA #D-0862-2017
Cite this page
“Hospira Infant Dextrose Injection Recall: Hair Particulates in Syringes.” GovInfoNow, updated October 8, 2026. https://govinfonow.com/recall/41641-hospira-infant-dextrose-injection-recall-hair-particulates-in-syringes. Based on FDA recall #D-0862-2017 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0862-2017%22&limit=1).
Why it’s dangerous
Human hair particles were found inside the syringes during testing. These particles could get into an infant's bloodstream during injection, potentially causing blockages or reactions.
Who’s affected
Parents or caregivers of infants using this specific dextrose injection product. Infants receiving the recalled syringes are at highest risk.
How to tell if you have this one
Check for the product name 'Infant 25% Dextrose Injection, USP, 2.5 g (250 mg/mL), 10 mL Unit of Use Single-dose Syringe' in a carton. The lot number starts with 58382EV and expires October 2017.
- Brand
Hospira- Category
Drug
What to do — step by step
Stop Using Now
Immediately stop using any affected syringes and contact Hospira for a replacement.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide in the USA and Puerto Rico” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA published this recall 40 days after the firm started it.
- Firm started the recall
- FDA classified it Class I
- Published in FDA’s Enforcement Report
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0862-2017 (April 21, 2017) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0862-2017 to see it in context.
- Plain-language summary written by qwen3:4b on October 8, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.